The GVK Case Files: Black And White Or Shades Of Gray?
This article was originally published in Scrip
OK, first the disclaimer: this isn't a defence of any firm that isn't up to scratch when it comes to quality. Fudging of data is totally unacceptable and non-adherence to Good Clinical Practice (GCP) or Good Manufacturing Practice (GMP) should attract the toughest regulatory action.
You may also be interested in...
Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.
Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.
Physicians may have new expectations from pharma sales reps in India amid COVID-19 and teleconsulting efforts will likely see a significant uptick, at least until the pandemic plateaus, a new survey finds.